

Sanofi, Thursday September 1, 2022, 12.45-13.45, Hall Jerusalem

Pompe disease, a new era: the latest avalglucosidase alfa clinical data and early real-world experiences

Chair: Andreas Hahn, Giesen, Germany

Introduction by Chair

Andreas Hahn, Giesen, Germany

COMET, Mini-COMET, and real-world evidence on avalglucosidase alfa in the United States: What data do we have so far?

Priya Kishnani, Durham, United States

Latest perspectives: A case report of switching from alglucosidase alfa to avalglucosidase alfa

Serena Gasperini, Milan Italy

Looking to the future: Avalglucosidase alfa in infants with Pompe disease (Baby-COMET) and impact of home infusion therapy on quality of life

Andreas Hahn, Giesen, Germany

Panel discussion and Q&A

Andreas Hahn, Giesen, Germany

Priya Kishnani, Durham, United States

Serena Gasperini, Milan Italy

sponsored by

sanofi